On March 31, 2025, Quanterix Corporation announced the inclusion of a new dried blood spot (DBS) extraction kit as part of its industry-leading Simoa assay kits. This announcement was made at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD).
This new extraction kit enables researchers to measure low-concentration biomarkers from dried blood spots, offering a more cost-effective and less invasive method for sample collection. Validation studies showed DBS samples tested with Simoa ALZpath p-Tau 217 and the extraction kit demonstrated a correlation of 0.75 to 0.86 to venous samples.
CEO Masoud Toloue stated that the DBS extraction kit represents a major step forward in making biomarker testing more accessible, with the potential to expand participation in Alzheimer’s research and clinical trials, particularly among under-represented populations.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.